142
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation

, , , , , & show all
Pages 731-737 | Published online: 10 Feb 2012

References

  • LaverdiereCLiuQYasuiYLong-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor StudyJ Natl Cancer Inst20091011131114019648511
  • ToYFSunRWChenYGold (III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivoInt J Cancer20091241971197919107930
  • LumCTYangZFLiHYGold (III) compound is a novel chemocytotoxic agent for hepatocellular carcinomaInt J Cancer20061181527153816206274
  • LiWXieYSunRWInhibition of Akt sensitizes neuroblastoma cells to gold (III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibitionBr J Cancer200910134234919550420
  • SunRWYCheCMThe anti-cancer properties of gold(III) compounds with dianionicporphyrin and tetradentate ligandsCoord Chem Rev200925316821691
  • PizzolatoJFSaltzLBThe camptothecinsLancet20033612235224212842380
  • SumitomoMKoizumiFAsanoTNovel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progressionCancer Res2008681631163518339841
  • BoigeVTaiebJHebbarMIrinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin levelEur J Cancer20064245645916427779
  • RomanelliSPeregoPGraziellaPCereniniNTortoretoMZuninoFIn vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systemsCancer Chemother Pharmacol1998413853909523734
  • PantazisPKozielskiAJVardemanDMPetryERGiovanellaBCEfficacy of camptothecin congeners in the treatment of human breast carcinoma xenograftsOncol Res199452732818012059
  • LiuYZhangBYanBEnabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxelInt J Mol Sci2011124395441321845085
  • JunYJJadhavVBMinJHStable and efficient delivery of docetaxel by micelle-encapsulation using a tripodalcyclotriphosphazene amphiphileInt J Pharm201242237438022079718
  • LuCLiuPEffect of chitosan multilayers encapsulation on controlled release performance of drug-loaded superparamagnetic alginate nanoparticlesJ Mater Sci Mater Med2011Epub Nov5
  • TrembleyJHUngerGMKormanVLNanoencapsulated anti- CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cellsCancer Lett2012315485822050909
  • MaedaHThe enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdv Enzyme Regul20014118920711384745
  • GaumetMVargasAGurnyRDelieFNanoparticles for drug delivery: the need for precision in reporting particle size parametersEur J Pharm Biopharm2008691917826969
  • StormGBelliotSODaemenTLasicDDSurface modification of nanoparticles to oppose uptake by the mononuclear phagocyte systemAdv Drug Deliv Rev1995173148
  • KoziaraJMOhJJAkersWSFerrarisSPMumperRJBlood compatibility of cetyl alcohol/polysorbate-based nanoparticlesPharm Res2005221821182816132346
  • LeePYZhuYZYanJJThe cytotoxic effects of lipidic formulated gold-porphyrin nanoparticles for the treatment of neuroblastomaNanotechnol Sci Appl201032328
  • CheCMSunRWYYuWYKoCBZhuNSunHGold (III) porphyrins as a new class of anti-cancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cellsChem Commun (Camb)2003141718171912877519
  • MaPDongXSwadleyCLDevelopment of idarubicin and doxorubicin solid lipid nanoparticles to overcome pgp-mediated multiple drug resistance in leukemiaJ Biomed Nanotechnol2009515116120055093
  • KumarVVChandrasekarDRamakrishnaSKishanVRaoYMDiwanPVDevelopment and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokineticsInt J Pharm200733516717517161566
  • De CesareMCalcaterraCPratesiGEradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapyClin Cancer Res2008145512551818765543
  • ChlenskiAGuerreroLJPeddintiRAnti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumorsMol Cancer2010913820525313
  • ShustermanSGruppSABarrRCarpentieriDZhaoHMarisJMThe angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical diseaseClin Cancer Res2001797798411309349
  • PhuangsabALorenceRMReichardKWPeeplesMEWalterRJNewcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administrationCancer Lett2001172273611595126
  • KebbekusBBPreparation of samples for metal analysisMitraSSample Preparation Techniques in Analytical ChemistryHoboken, NJJohn Wiley & Sons2003
  • DrinGMazelMClairPMathieuDKaczorekMTemsamaniJPhysico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinityEur J Biochem20012681304131411231282
  • BraetFWisseEStructural and functional aspects of liver sinusoidal endothelial cell fenestrae: a reviewComp Hepatol20021112437787
  • YuanFDellianMFukumuraDVascular permeability in a human tumor xenograft: molecular size dependence and cutoff sizeCancer Res199555375237567641188
  • EisenbreyJRSoulenMCWheatlyMADelivery of encapsulated doxorubicin by ultrasound-mediated size reduction of drug-loaded polymer contrast agentsIEEE Trans Biomed Eng201057242819709952
  • FuldaSTumor resistance to apoptosisInt J Cancer200912451151519003982